McGready 2001.

Study characteristics
Methods	RCT Trial duration: 17 months (treatment period: 18 weeks)
Participants	Adults or children living in malaria‐endemic regions (women 3 to 7 months pregnant) High‐risk population (refugees) Endemic region for P vivax Participants not screened for hypnozoites
Interventions	Topical repellent: 20% DEET added to Thanaka (popular local cosmetic) Controls: Thanaka alone Co‐intervention: none Treatment arms: Intervention: 449 Controls: 448
Outcomes	Malaria infection incidence: new Plasmodium spp. infections confirmed through thick or thin blood smears, RDTs, or polymerase chain reaction (PCR) Incidence of recorded adverse events (including skin irritation, local pain, eye irritation, irritation of upper airways, nausea, vomiting, headaches, dizziness or confusion, allergic or anaphylactic reactions, and systemic toxicity) Malaria prevalence Anaemia (haemoglobin < 8 g/dL) Adherence to regular usage of the intervention (defined based on recommendations provided by researchers to participants of individual trials)
Notes	Carried out in camps for displaced people of the Karen ethnic minority in Thailand Funded by the Danish Bilharziasis Laboratory and was part of the Wellcome‐Mahidol University of Oxford Tropical Medicine Research Programme funded by the Wellcome Trust